Protagonist Q1 net loss $33.7M; positive Phase 2b data for JNJ-2113; cash runway to 2025

Protagonist Therapeutics, Inc

2023-Q1 EPS reported -$0.67

Net loss $33.7M ($0.67/share) vs $20.9M loss in Q1 2022; license revenue zero (prior year $25.7M milestone).
Positive Phase 2b FRONTIER 1 topline data for JNJ-2113 in psoriasis: PASI-75 met across all dose groups vs placebo.
Phase 2 REVIVE rusfertide data: 69.2% responders vs 18.5% placebo (p=0.0003); phlebotomy free 92.3% vs placebo.
Closed public offering of 5.75M shares at $20 each; net proceeds $108.1M; cash runway now through end of 2025.
Cash and marketable securities $230.8M; R&D expenses $27.4M (down from $36.3M); G&A $8.6M (down from $10.5M).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Protagonist Therapeutics, Inc reported the first quarter ended March 31, 2023 results: revenue zero.

Period: the first quarter ended March 31, 2023
Revenue: zero
Result: reported results

Exact text from the filing

License and collaboration revenue for the first quarter 2023 was zero, as compared to $25.7 million for the first quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Protagonist Therapeutics, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-056018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.